יסאפילי - Yesafili
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | S01LA Antineovascularisation agents |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ××××××ת ××¢×× - INTRAVITREAL |
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Yesafili is indicated for adults for the treatment of ⢠neovascular (wet) age-related macular degeneration (AMD) ⢠visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) ⢠visual impairment due to diabetic macular oedema (DME) ⢠visual impairment due to myopic choroidal neovascularisation (myopic CNV) |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 ××× ×¢××× ×ר××¤× Â |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ס×פ××× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BIOSIMILAR COLLABORATIONS IRELAND LIMITED, IRLAND |
| ×©× ××¢× ×ר×ש×× | DEXCEL LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2024. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 07/06/2025 |
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
- ×××©×¨× ×ר××§× ×תק××ת ×× ×××× ×ק×××¨× ×©××פשרת ×ר××× ×¢× ××××©× ×××ש×× ××× ×××רק×ת
- ××פ×× ×¢× ×ר×××ס×××××× ××××× ×ש×פ×ר ××××פ××× ×¢× ×צקת ×ק××ר×ת ס××רת×ת
- ××¢×××ת ××××××ת Brolucizumab ×¢××ר ×צקת ×ק××ר×ת ס××רת×ת
- Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration
- Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study
השינוי האחרון נעשה בֹ־7 ביוני 2025 ב־09:55